Study of Prostate Specific Antigen, Alkaline Phosphatase and Vitamin B12 in Prostate Cancer

Objective: This study aimed to find the relative risks of prostate cancer incidence associated with screening by serum prostate-specific antigen (PSA), alkaline phosphatase (ALP) and vitamin B12 levels.

Methods: Serum samples of 488 subjects above 40 years without treatment or puncture/rectal examination were screened for PSA levels using Chemiluminescence. Prostate cancer cases and control groups were analysed for vitamin B12 using Chemiluminescence and alkaline phosphatase using fully automated chemistry analyser. The relation of ALP and Vitamin B12 to levels of PSA in prostate cancer was examined.

Results: Incidence rate for the screening on the risk of prostate cancer by PSA levels and metastasis involvement was significant. Out of 488 screened subjects, 347 were within normal range according to age reference values, 30 were showing prostate cancer, and 111 were with the high risk of metastasis. Results of the case-control analysis showed a positive correlation among ALP and PSA levels and negative with vitamin B12.

Conclusions: Benefits of PSA screening varies with age group according to blood PSA levels. For men with a PSA level in different age groups screening and treatment depends upon individual decision, pain and clinical examination.